Article Versions Notes

Alzoubi A, Shirazi H, Alrawashdeh A, AL-Dekah AM, Ibraheem N, Kheirallah KA. The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature. Pharmaceutics. 2024; 16(2):167. https://doi.org/10.3390/pharmaceutics16020167

Alzoubi, Abdallah, Hassan Shirazi, Ahmad Alrawashdeh, Arwa M. AL-Dekah, Nadia Ibraheem, and Khalid A. Kheirallah. 2024. "The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature" Pharmaceutics 16, no. 2: 167. https://doi.org/10.3390/pharmaceutics16020167

Alzoubi, A., Shirazi, H., Alrawashdeh, A., AL-Dekah, A. M., Ibraheem, N., & Kheirallah, K. A. (2024). The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature. Pharmaceutics, 16(2), 167. https://doi.org/10.3390/pharmaceutics16020167